Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tobramycin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  Next»
    Study title: Comparative evaluation of aztreonam and tobramycin plus azlocillin in pulmonary exacerbations of cystic fibrosis
    Active substance: AZTREONAM
    Study summary document link (including results):
    View full study record
    Document reference: 46686
    Study title: Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Protzko E, Bowman L, Abelson M, Shapiro A; AzaSite Clinical Study Group. Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3425-9.
    Active substance: ERYTHROMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 26566
    Study title: [A nonsteroidal inflammation inhibitor in chronic conjunctivitis] Stodtmeister R, Marquardt R. Fortschr Ophthalmol. 1986;83(2):199-202. [A nonsteroidal inflammation inhibitor in chronic conjunctivitis] Stodtmeister R, Marquardt R. Fortschr Ophthalmol. 1986;83(2):199-202.
    Active substance: DICLOPHENAC AND TOBRAMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 26092
    Study title: Comparison of the efficacy of diclofenac and betamethasone following strabismus surgery. Wright M, Butt Z, McIlwaine G, Fleck B. Br J Ophthalmol. 1997 Apr;81(4):299-301. Comparison of the efficacy of diclofenac and betamethasone following strabismus surgery. Wright M, Butt Z, McIlwaine G, Fleck B. Br J Ophthalmol. 1997 Apr;81(4):299-301.
    Active substance: DICLOPHENAC AND TOBRAMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 26090
    Study title: Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis. D'Angelo G, Lambiase A, Cortes M, Sgrulletta R, Pasqualetti R, Lamagna A, Bonini S. Graefes Arch Clin Exp Ophthalmol. 2003 Mar;241(3):192-5;Epub 2003 Feb 15. Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis. D'Angelo G, Lambiase A, Cortes M, Sgrulletta R, Pasqualetti R, Lamagna A, Bonini S. Graefes Arch Clin Exp Ophthalmol. 2003 Mar;241(3):192-5;Epub 2003 Feb 15.
    Active substance: DICLOPHENAC AND TOBRAMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 26088
    Study title: Treatment of severe lower respiratory tract infections with Ro 13-9904 in paediatric patients. An open comparative trial versus tobramycin. Prof. M B Canani, Napoli, Italy, centre No. 11.6107, cases Nos. 1-40. 29.09.1983
    Active substance: CEFTRIAXONE
    Study summary document link (including results):
    View full study record
    Document reference: 23594
    Study title: Prospective, Randomized, Third-Party Blind, Study to Compare the Safety and Efficacy of Ciprofloxacin (Sequential IV/PO) with intravenous Ceftazidime and Tobramycin in the Treatment of Pediatric Cystic Fibrosis Patients with Acute Pulmonary Exacerbation.
    Active substance: CIPROFLOXACIN
    Study summary document link (including results): 512.pdf
    View full study record
    Document reference: 24224
    Study title: A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children.Gross RD, Hoffman RO, Lindsay RN. Clin Pediatr (Phila). 1997 Aug;36(8):435-44 Comment in: Clin Pediatr (Phila). 1997 Aug;36(8):445-8. PMID: 9272317. A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children.Gross RD, Hoffman RO, Lindsay RN. Clin Pediatr (Phila). 1997 Aug;36(8):435-44 Comment in: Clin Pediatr (Phila). 1997 Aug;36(8):445-8. PMID: 9272317.
    Active substance: DEXAMETHASONE AND TOBRAMYCIN
    Study summary document link (including results): Comparison of ciprofloxacin and tobramycin in bacterial conj.pdf
    View full study record
    Document reference: 25753
    Study title: [Conjunctivitis of bacterial origin in children. Local antibiotic treatment with tobramycin collyrium] Fioretti GM, Campanari C. Pediatr Med Chir. 1989 Jul-Aug;11(4):421-3. [Conjunctivitis of bacterial origin in children. Local antibiotic treatment with tobramycin collyrium] Fioretti GM, Campanari C. Pediatr Med Chir. 1989 Jul-Aug;11(4):421-3.
    Active substance: DEXAMETHASONE AND TOBRAMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 25754
    Study title: Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. Jackson WB, Low DE, Dattani D, Whitsitt PF, Leeder RG, MacDougall R. Can J Ophthalmol. 2002 Jun;37(4):228-37; discussion 237. Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. Jackson WB, Low DE, Dattani D, Whitsitt PF, Leeder RG, MacDougall R. Can J Ophthalmol. 2002 Jun;37(4):228-37; discussion 237.
    Active substance: DEXAMETHASONE AND TOBRAMYCIN
    Study summary document link (including results): Treatment of acute neonatal bacterial conjunctivitis.pdf
    View full study record
    Document reference: 25752
    Study title: COMPARATIVE EVALUATION OF CLINDAMYCIN VS CLINDAMYCIN PLUS TOBRAMYCIN IN THE TREATMENT OF PELVIC INFLAMMATORY DISEASE
    Active substance: CLINDAMYCIN
    Study summary document link (including results): M11000093 EMA Pediatrics Web Synopsis.pdf
    View full study record
    Document reference: 24368
    Study title: Fusidic acid versus tobramycin in suspected bacterial conjunctivitis
    Active substance: FUSIDIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 28680
    Study title: A Formulation of Aerosolized Tobramycin (BramitobR) in the Treatment of Patients with Cystic Fibrosis and Pseudomonas aeruginosa Infection A Double-Blind, Placebo-Controlled, Multicenter StudyChuchalinet al, Pediatr Drugs 2007; 9 Suppl. 1: 21-31
    Active substance: TOBRAMYCIN
    Study summary document link (including results): DM.RS.10000.002.04 publication.pdf
    View full study record
    Document reference: 49196
    Study title: Efficacy, Safety, and Local Pharmacokinetics of Highly Concentrated Nebulized Tobramycin in Patients with Cystic Fibrosis Colonized with Pseudomonas aeruginosaLenoir et al, Pediatr Drugs 2007; 9 Suppl. 1: 11-20, 1174-5878/07/0001-0011/
    Active substance: TOBRAMYCIN
    Study summary document link (including results): DM.PR.10000.001.01 publication.pdf
    View full study record
    Document reference: 49195
    Study title: Tobramycin sulfate elimination in premature infants. Arbeter AM, Saccar CL, Eisner S, Sarni E, Yaffe SJ. J Pediatr. 1983 Jul;103(1):131-5.
    Active substance: TOBRAMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 48896
    Study title: A COMPARISON OF CEFOPERAZONE PLUS SULBACTAM VERSUS AMPICILLIN PLUS TOBRAMYCIN IN THE TREATMENT OF PATIENTS WITH BILIARY TRACT INFECTIONS
    Active substance: SULBACTAM
    Study summary document link (including results):
    View full study record
    Document reference: 42655
    Study title: Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Protzko E, Bowman L, Abelson M, Shapiro A; AzaSite Clinical Study Group. Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3425-9.Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Protzko E, Bowman L, Abelson M, Shapiro A; AzaSite Clinical Study Group. Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3425-9.
    Active substance: TOBRAMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 25751
    Study title: Protzko E, Bowman L, Abelson M, Shapiro A; AzaSite Clinical Study Group. Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3425-9.Protzko E, Bowman L, Abelson M, Shapiro A; AzaSite Clinical Study Group. Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3425-9.
    Active substance: TOBRAMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 44821
    Study title: A comparison of 0.3% Tobramycin Ophthalmic Solution (TOBREX New) vs TOBREX Ophthalmic Solution (TOBREX) for Treatment of Bacterial Conjunctivitis (C9998).
    Active substance: TOBRAMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 44819
    Study title: Clinical evaluation of TOBRADEX Ophthalmic Suspension versus Tobramycin Ophthalmic Solution (TOBREX) (C9192),
    Active substance: TOBRAMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 44818
    1  2  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 13:26:09 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA